GSK plc Files 6-K on Share Transactions
Ticker: GLAXF · Form: 6-K · Filed: Sep 11, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Sep 11, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-transaction, 6-K, foreign-private-issuer
TL;DR
GSK plc filed a 6-K on 9/11/25 about share transactions.
AI Summary
GSK plc filed a Form 6-K on September 11, 2025, reporting a transaction in its own shares. The filing indicates that GSK plc, formerly GlaxoSmithKline PLC, is a foreign private issuer based in London, UK, and operates in the pharmaceutical preparations industry.
Why It Matters
This filing provides transparency regarding GSK's activities in its own shares, which can be relevant for investors monitoring share buybacks or issuances.
Risk Assessment
Risk Level: low — This is a routine filing reporting on share transactions, not indicating any immediate financial distress or significant operational change.
Key Players & Entities
- GSK plc (company) — Registrant
- GlaxoSmithKline PLC (company) — Former company name
- September 11, 2025 (date) — Filing date
- 79 New Oxford Street, London, WC1A 1DG (address) — Principal executive office
FAQ
What type of transaction is GSK plc reporting in this 6-K filing?
GSK plc is reporting a 'Transaction in own shares'.
When was this Form 6-K filed with the SEC?
The Form 6-K was filed on September 11, 2025.
What is GSK plc's principal executive office address?
GSK plc's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Is GSK plc required to file annual reports on Form 20-F or 40-F?
GSK plc indicates it files annual reports under cover of Form 20-F.
What was GSK plc's former company name?
GSK plc was formerly known as GlaxoSmithKline PLC.
Filing Stats: 2,893 words · 12 min read · ~10 pages · Grade level 3.6 · Accepted 2025-09-11 07:31:18
Filing Documents
- a8595y.htm (6-K) — 2253KB
- 0001654954-25-010634.txt ( ) — 2254KB
From the Filing
IN OWN SHARES a8595y     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of September 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .                                   Transaction in own shares   GSK plc (the " Company ") announces today   acting through its corporate stockbroker, Merrill Lynch International (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.     Date of purchase:   10 September 2025   Aggregate number of ordinary shares of  31¼  pence each purchased:   213,147   Lowest price paid per share (GBp):   1,480.50p   Highest price paid per share (GBp):   1,500.00p   Volume-weighted average price paid per share (GBp):   1,486.77p     The purchased shares will be held as Treasury shares.   Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 28,232,207 ordinary shares.   Following the above purchase, the Company will hold 246,366,590 ordinary shares in treasury and have 4,069,035,137 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is 4,069,035,137. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is   6.05 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.     Schedule of Purchases   Shares purchased:      GSK plc (ISIN: GB00BN7SWP63)   Date of purchases:     10 September 2025   Investment firm:        Merrill Lynch International     Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share) (GBp)   Lowest price paid (per ordinary share) (GBp)   Volume weighted average price paid (per ordinary share) (GBp)   London Stock Exchange (XLON)   213,147   1,500.00p   1,480.50p   1,486.77p   CBOE (CHIX)   0   -   -   -   CBOE (BATE)   0   -   -   -       Individual transactions:   Number ofShares   Price per Share (GBp)   Tradingvenue   Date oftransaction   Time oftransaction   Transaction reference number   53   1,493.00    XLON   10-Sep-2025   08:00:25   0XL061000000000088VTKI   995   1,493.00    XLON   10-Sep-2025   08:00:25   0XL061700000000088VU0U   49   1,494.50    XLON   10-Sep-2025   08:00:28   0XL064000000000088VTTS   54   1,495.00    XLON   10-Sep-2025   08:00:28   0XL067000000000088VTTF   51   1,494.50    XLON   10-Sep-2025   08:00:29   0XL06A000000000088VTU4   18   1,497.00    XLON   10-Sep-2025   08:01:04   0XL061000000000088VTOO   23   1,496.00    XLON &#x